A Study to Evaluate INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasms
Key claim: A phase 1 study is evaluating the safety, tolerability, MTD, and recommended expansion dose of INCA033989 as monotherapy or in combination with ruxolitinib in MPN patients.
Abstract
This study is being conducted to evaluate the safety, tolerability, and dose-limiting toxicity (DLT) and determine the maximum tolerated dose (MTD) and/or recommended dose(s) for expansion (RDE) of INCA033989 administered as a monotherapy or in combination with ruxolitinib in participants with myeloproliferative neoplasms.
Why this matters
INCA033989 represents a new investigational agent entering the MPN therapeutic pipeline, with a phase 1 design that allows both monotherapy assessment and ruxolitinib-combination evaluation. Its dual-arm structure mirrors the now-standard development pattern for novel MPN agents, where the ruxolitinib backbone is leveraged to assess additive benefit. Mechanism details remain to be disclosed, but the Incyte naming convention places it alongside other Incyte MPN candidates (INCB057643, INCA035784, INCA036978) under active investigation.